Marlene R. Amoruso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marlene R. Amoruso has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Guillermo Hidalgo
Hackensack Meridian School of Medicine
2 shared publications - Ibrahim Batal
Pathology & Cell Biology, Columbia University Irving Medical Center, New York, USA
2 shared publications - Kenneth Lieberman
Division of Pediatric Nephrology, Department of Pediatrics Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center Hackensack New Jersey USA
2 shared publications - Michael J. Goldstein
Division of Transplantation, Department of Surgery Hackensack Meridian Health Hackensack New Jersey USA
2 shared publications - Namarata G. Jain
Division of Pediatric Nephrology, Department of Pediatrics Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center Hackensack New Jersey USA
2 shared publications - Ally Watson
Division of Pediatric Nephrology, Department of Pediatrics Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center Hackensack New Jersey USA
1 shared publication
Latest Publications
- 9 June 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (5) , e70116
Daratumumab for Treatment of Acute Antibody‐Mediated Rejection in a Pediatric Kidney Transplant Recipient
Background: Daratumumab, an anti‐CD38 monoclonal antibody, has shown efficacy as a potential treatment for antibody‐mediated rejection (ABMR) following kidney transplantation in adults. Methods: We present a case demonstrating the use of daratumumab for the management of ABMR in a pediatric kidney transplant recipient. Results: The patient underwent a living‐unrelated donor renal transplant with a post‐transplant course complicated by active ABMR. The patient received a total of four daratumumab infusions with a subsequent decrease in serum creatinine, serum donor‐specific antibody levels, and donor‐derived cell‐free DNA (dd‐cfDNA), which remained low 1 year following treatment. Conclusions: Daratumumab may be a promising treatment consideration for the management of ABMR in pediatric patients following renal transplantation, though further research is needed to better understand its efficacy and side effects. DD‐cfDNA may also be a promising tool to monitor treatment response in conjunction with more traditional methods.
- 9 June 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (5) , e70116
Daratumumab for Treatment of Acute Antibody‐Mediated Rejection in a Pediatric Kidney Transplant Recipient
Background: Daratumumab, an anti‐CD38 monoclonal antibody, has shown efficacy as a potential treatment for antibody‐mediated rejection (ABMR) following kidney transplantation in adults. Methods: We present a case demonstrating the use of daratumumab for the management of ABMR in a pediatric kidney transplant recipient. Results: The patient underwent a living‐unrelated donor renal transplant with a post‐transplant course complicated by active ABMR. The patient received a total of four daratumumab infusions with a subsequent decrease in serum creatinine, serum donor‐specific antibody levels, and donor‐derived cell‐free DNA (dd‐cfDNA), which remained low 1 year following treatment. Conclusions: Daratumumab may be a promising treatment consideration for the management of ABMR in pediatric patients following renal transplantation, though further research is needed to better understand its efficacy and side effects. DD‐cfDNA may also be a promising tool to monitor treatment response in conjunction with more traditional methods.
- 1 May 2023
- Published by Wiley in Pediatric Transplantation
- Vol. 27 (5) , e14535
CMV‐associated collapsing focal segmental glomerulosclerosis after kidney transplant in a pediatric patient
Background: Cytomegalovirus (CMV) is a significant cause of morbidity among immunocompromised patients who have undergone kidney transplantation and is known to rarely induce collapsing focal segmental glomerulosclerosis (FSGS) among adults.Methods: We present the first reported case of CMV‐induced collapsing FSGS in a pediatric patient after kidney transplant.Results: Our patient underwent a deceased donor kidney transplant due to end‐stage renal disease secondary to lupus nephritis. Approximately 4 months after transplantation, he developed signs of worsening kidney function in the setting of CMV viremia and was found to have collapsing features of FSGS on kidney transplant biopsy. He was managed with a prompt escalation of antiviral therapy along with a reduction of immunosuppression and recovered without significant complication. At follow‐up, he continued to have undetectable CMV titers, creatinine within normal limits, and no significant proteinuria.Conclusion: This report demonstrates CMV as a cause of collapsing FSGS and should be considered among pediatric transplant recipients who present with acute kidney injury, as should early assessment of APOL1 genetic status in both donor and recipient.
- 1 May 2023
- Published by Wiley in Pediatric Transplantation
- Vol. 27 (5) , e14535
CMV‐associated collapsing focal segmental glomerulosclerosis after kidney transplant in a pediatric patient
Background: Cytomegalovirus (CMV) is a significant cause of morbidity among immunocompromised patients who have undergone kidney transplantation and is known to rarely induce collapsing focal segmental glomerulosclerosis (FSGS) among adults.Methods: We present the first reported case of CMV‐induced collapsing FSGS in a pediatric patient after kidney transplant.Results: Our patient underwent a deceased donor kidney transplant due to end‐stage renal disease secondary to lupus nephritis. Approximately 4 months after transplantation, he developed signs of worsening kidney function in the setting of CMV viremia and was found to have collapsing features of FSGS on kidney transplant biopsy. He was managed with a prompt escalation of antiviral therapy along with a reduction of immunosuppression and recovered without significant complication. At follow‐up, he continued to have undetectable CMV titers, creatinine within normal limits, and no significant proteinuria.Conclusion: This report demonstrates CMV as a cause of collapsing FSGS and should be considered among pediatric transplant recipients who present with acute kidney injury, as should early assessment of APOL1 genetic status in both donor and recipient.